---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007047"
form_type: "8-K"
ticker: null
cik: "0001722964"
company_name: "Y-mAbs Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:13:03.331636+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Y-mAbs reports Q1 2024: U.S. DANYELZA rev up 11% to $18.6M; net loss $0.15/share

## Summary
- U.S. DANYELZA net revenue $18.6M (+11% YoY); worldwide $19.4M (-4% YoY on international stocking shipment in Q1 2023).
- Net loss $6.6M ($0.15 per share), relatively flat vs Q1 2023 loss of $6.4M.
- Cash $75.7M, cash burn $2.9M in Q1; FY2024 guidance reaffirmed: rev $95-100M, cash runway into 2027.
- CFO Bo Kruse to resign upon successor appointment; search firm retained.
- Adium launched DANYELZA in Brazil/Mexico in April; five new U.S. accounts added in Q1.

## SEC filing metadata
- accession: 0001558370-24-007047
- form_type: 8-K
- cik: 0001722964
- company_name: Y-mAbs Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/0001558370-24-007047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/ymab-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007047
- JSON: https://secwatch.observer/filing/0001558370-24-007047.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007047.txt

## Key facts
- Earnings Releases
  Y-mAbs Therapeutics, Inc. updated its the quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: the quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 7, 2024, Y-mAbs Therapeutics, Inc., announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/0001558370-24-007047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.